KINTOR PHARMA-B (09939) has announced that, considering the long tenure of its current auditor, the time is appropriate to rotate audit firms to uphold strong corporate governance and ensure audit independence and objectivity. Accordingly, the incumbent auditor will retire upon the conclusion of the upcoming annual general meeting scheduled for June 18, 2026. Following a recommendation from the audit committee, the board has resolved to propose the appointment of a new auditor effective from the conclusion of that meeting, subject to shareholder approval at the annual general meeting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments